ImmuPharma (CHIX:IMML) Beginning Cash Position: £0.40 Mil (As of Dec. 2025)


What is ImmuPharma Beginning Cash Position?

ImmuPharma CHIX:IMML Beginning Cash Position is £0.40 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

ImmuPharma's Beginning Cash Position for the quarter that ended in Dec. 2025 was £0.40 Mil.

ImmuPharma's quarterly Beginning Cash Position declined from Dec. 2024 (£1.08 Mil) to Jun. 2025 (£0.24 Mil) but then increased from Jun. 2025 (£0.24 Mil) to Dec. 2025 (£0.40 Mil).

ImmuPharma's annual Beginning Cash Position declined from Dec. 2023 (£0.67 Mil) to Dec. 2024 (£0.21 Mil) but then increased from Dec. 2024 (£0.21 Mil) to Dec. 2025 (£0.24 Mil).

ImmuPharma Beginning Cash Position Related Terms

ImmuPharma Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for ImmuPharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuPharma Beginning Cash Position Chart

ImmuPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.86 1.65 0.67 0.21 0.24

ImmuPharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.21 1.08 0.24 0.40

ImmuPharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of £0.40 Mil mean?
ImmuPharma (CHIX:IMML) has a Beginning Cash Position of £0.40 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ImmuPharma and its competitors.
Is ImmuPharma's Beginning Cash Position too high?
ImmuPharma's current Beginning Cash Position is £0.40 Mil.
How does ImmuPharma's Beginning Cash Position compare to VRTX and REGN?
ImmuPharma's Beginning Cash Position of £0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ImmuPharma and its competitors. ImmuPharma's current Beginning Cash Position is £0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuPharma stock overvalued right now?
ImmuPharma (CHIX:IMML) has a current Beginning Cash Position of £0.40 Mil. The current Beginning Cash Position is £0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For ImmuPharma (CHIX:IMML), the current Beginning Cash Position is £0.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuPharma Business Description

Other Exchanges IMM:UK25I:Germany
Address One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.